In 2017 (Table 4), approval was given to olaratumab (Lartruvo), a targeted antibody against the platelet-derived growth factor receptor alpha (PDGFRα), for patients with soft tissue sarcoma who were left without options to be treated by surgery and radiation [99]. Here, PDGFRA is linked to soft tissue sarcoma.